We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » NICE Endorses Alexion’s HPP Drug Strensiq, Gilead’s Hepatitis C Therapy Epclusa
NICE Endorses Alexion’s HPP Drug Strensiq, Gilead’s Hepatitis C Therapy Epclusa
The UK’s price watchdog has recommended reimbursement for Alexion Pharma’s Strensiq to treat perinatal- and infantile-onset hypophosphatasia and Gilead’s Epclusa to block the spread of hepatitis C virus genotypes to new cells, provided the companies discount the prices.